Investment allows Biofortuna to expand for continued growth

Biofortuna, a UK-based molecular diagnostics company developing novel IVD kits, is expanding for continued growth with a £2.1m investment.

The new funds will enable the business to expand its manufacturing operations in line with sales growth, support applications for regulatory approvals, most notably in the US market, and broaden its product range to address companion diagnostics, antibody screening and disease identification.

The funding included a new investor, the Foresight Group (UK), which has previously worked with Dr Simon Douglas, the chief executive officer of Biofortuna.